| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Completion of Acquisition or Disposition of Assets
Reported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers; FDA granted TX2100 Fast Track designation for Hereditary... |
| 29 Sep 2026 |
8-K: Other Events
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results anticipated in early Q1 2027 |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027 |
| 23 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modul... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. Topline results showed T... |
| 24 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
TX2100: A Differentiated Anti-Angiogenic Therapy for HHT and Other Bleeding Disorders FEBRUARY 24, 2026 Exhibit 99.2 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction... |
| 30 Oct 2025 |
8-K: Other Events
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to expand the th... |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 6, 2025, Tectonic Therapeutic, Inc. (the “Company”) held its 2025 Annual General Meeting of Stockholders (the “Annual General Meeting”). As of April 14, 2025, the record date for the Annual General Meeting, 18,671,229 shares of c... |
| 19 May 2025 |
8-K: Other Events
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejecti... |
| 20 Mar 2025 |
8-K: Results of Operations and Financial Condition
TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH... |
| 03 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 3, 2025, by and among Tectonic Therapeutic, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreeme... |
| 30 Jan 2025 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.1 TX45 Phase 1b PH-HFpEF Interim Data Release for Single Dose Hemodynamic Trial January 2025 |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Innovating GPCR-Targeted Therapies to Reach Large Untapped Market Opportunities JANUARY 2025 |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early Q2’2025 |
| 19 Sep 2024 |
8-K: Regulation FD Disclosure
Exhibit 99.2 Transforming and Innovating the Discovery and Development of Novel, Class Leading GPCR-Targeted Therapies S e p t e m b e r 2 0 2 4 |
Loading...